For biotech investors, healthcare professionals, and science enthusiasts — this interview features Cuong Do, President & CEO of BioVie (NASDAQ: BIVI), providing an exciting update on the company’s clinical progress in Parkinson’s disease and Long COVID.
BioVie’s investigational therapy aims to become the first new Parkinson’s treatment in over 50 years, using a novel mechanism that targets tumor necrosis factor alpha (TNF-α) to reduce inflammation and insulin resistance in the brain. Backed by major research partners like the Michael J. Fox Foundation, Mayo Clinic, Mount Sinai, Yale, and UCSF, BioVie expects its Parkinson’s trial to be fully enrolled by year-end, with top-line data anticipated by April or May next year.
Do also discusses the company’s Long COVID trial, which addresses chronic fatigue, brain fog, and inflammation linked to lingering viral proteins — using the same TNF-α–blocking mechanism to help millions still suffering post-infection.
Learn more about ongoing trials and enrollment at bioviepharma.com.
Watch more episodes of NewsOut for insight into companies driving the future of biotech and medical innovation.